




RealRate

PHARMACEUTICAL 2019

Hepion Pharmaceuticals Inc
Rank 306 of 361



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Hepion Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Hepion Pharmaceuticals Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Hepion Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 130% points.

The company's Economic Capital Ratio, given in the ranking table, is 135%, being 114% points below the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	2,968
Cost of Goods Sold	0
Intangible Assets	1,871
Liabilities, Current	2,850
Liabilities, Non-Current	0
Other Assets	3,318
Other Compr. Net Income	0
Other Expenses	-197
Other Liabilities	3,364
Other Net Income	4,948
Other Revenues	0
Property and Equipment	32
Research and Development	7,594
Selling, General and Administrative Expense	7,000

Output Variable	Value in 1000 USD
Assets	8,189
Liabilities	6,214
Expenses	14,397
Revenues	0
Stockholders Equity	1,975
Net Income	-9,449
Comprehensive Net Income	-9,449
BaseVar	16,874
ECR before Limited Liability	-71%
Economic Capital Ratio	135%